Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
1997-11-06
2002-06-11
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C514S002600, C514S008100, C514S012200
Reexamination Certificate
active
06403077
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to chimeric proteins which include a cytokine and an enzymatically inactive polypeptide, and therapeutic uses thereof.
Cytokines have a wide range of effects on cell growth and differentiation. The value of certain cytokines has been recognized, including, for example, IL-2 for promoting the growth of activated T cells, B cells, LAK cells, and NK cells; IL-3 for promoting the growth of pluripotent hematopoietic progenitor cells; granulocyte macrophage-colony stimulating factor (GM-CSF) for promoting the growth and differentiation of neutrophils and macrophages, and for activating macrophages; kit ligand for promoting basophil and mast cell differentiation; IL-4 for promoting B cell proliferation, enhancing class II gene expression, enhancing IgG1 and IgE production, and promoting activated T cell proliferation and effector cell function; IL-5 for enhancing IgA production and stimulating eosinophil growth; IL-6 for transiently blocking myeloma growth, inducing immunoglobulin production, and inducing plasma cell and hepatocyte growth; IL-7 for inducing immature and mature B and T cell growth; and interferon-&agr; and -&bgr; for their antiviral activity against papilloma viruses, hepatitis viruses, and herpes virus, and for treating hairy cell leukemia, myeloma, and other hematopoietic malignancies. Some additional functions of cytokines are summarized below.
Reported IL-1 activities include activation of T cells; induction of IL-2 receptor expression and cytokine gene expression; enhancement of collagenase, stromelysin, prostaglandin, and PDGF-AA synthesis by fibroblasts; co-stimulation of thymocyte proliferation; stimulation of pre-B cell differentiation; co-stimulation of B cell proliferation and Ig secretion; augmentation of IL-2 and IFN-induced activation of NK-mediated cytotoxicity; induction of adhesion molecule expression by endothelial cells; osteoblast and endothelial cell activation; enhancement of collagen production by epidermal cells; modulation of reparative functions following tissue injury; induction of insulin secretion; and &bgr;-islet cell cytotoxicity.
IL-1 has also been shown to stimulate the release of factors associated with the growth and differentiation of cells from myeloid and lymphoid lineages in vitro. IL-1 is thought to induce the production of granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) by human marrow stromal cells; induce the production of GM-CSF and G-CSF by human dermal fibroblasts; and induce the production of GM-CSF by human peripheral blood lymphocytes. IL-1 also stimulates hematopoiesis by up-regulating receptors for colony stimulating factors and inducing the proliferation of pluripotent progenitors in the bone marrow. IL-1 has been shown to protect mice from otherwise lethal doses of radiation which indicates that this protein is useful in cancer therapy. Also, IL-1 has been shown to accelerate wound healing, presumably due to its ability to induce angiogenesis and fibroblast activation.
IL-2 has been reported to participate in the activation, tumoricidal activity, and growth of T cells, NK cells, and LAK cells; augment B cell growth and immunoglobulin production; augment IFN-&ggr; production; induce IL-6 production by human monocytes; modulate histamine release by stimulated basophils; and modulate expression of the IL-2 receptor. Applications of IL-2 include anti-tumor therapy employing IL-2-activated LAK and TIL cell infusions; augmentation of IL-2 levels in treating immunodeficiency disorders, and increasing of NK cell activity following bone marrow transplant.
Reported functions of IL-3 include stimulating the proliferation of mast cell lines; stimulating the formation of neutrophils, macrophages, megakaryocytes, basophils, eosinophils, and mast cells from isolated hematopoietic progenitors; enhancing growth of certain human T lymphocytes; and potentiating the activity of eosinophils, basophils, and monocytes. It has been shown that IL-3 exerts its ability to support multi-lineage colony formation early in the development of multipotent progenitors. IL-3 exhibits synergy with Stem Cell Factor (kit ligand) in inducing human CD34
+
cells to form basophils and mast cells. IL-3 has been used successfully in combination with factors such as GM-CSF to stimulate hematopoiesis in primates. In addition, sequential administration of IL-3 and IL-6 in primates stimulates thrombopoiesis. In vitro studies suggest that IL-3 can be used to reverse the hematopoietic toxicity associated with AZT treatment. Recombinant IL-3 has also been used in clinical trials in combination with other colony stimulating factors as a treatment for aplastic anemia.
IL-4 has been reported to be useful for up-regulating MHC Class II expression in resting B cells; enhancing IgG1, IgE, and sIgM production by B cells; up-regulating Fc receptor expression for IgE on B cells and monocytes; increasing viability and growth of normal resting cells and certain T cell lines; co-stimulating growth in certain mast cell lines; maintaining Lyt-2
−
/L3T4
31
thymic stem cells; promoting thymocyte-maturation; enhancing the proliferation of granulocyte-macrophage progenitors, erythrocyte progenitors, and meqakaryocytes in response to G-CSF, EPO, and IL-1, respectively; inhibiting human breast carcinoma cell growth in culture; inducing progression in B cells; inducing tumoricidal activity in cultured macrophages; and regulating adhesion molecule expression on endothelial cells.
Additionally, IL-4 is thought to act in combination with IL-1 as an autocrine growth factor for antigen-specific T cells to enhance antigen presentation and phagocytosis in macrophages. IL-4 not only enhances the development of cytotoxic T lymphocytes (CTL) from resting murine cells, but it also induces LAK activity. As a multifunctional cytokine that is reported to augment certain T and B cell responses, the therapeutic functions of IL-4 include reconstitution of cellular and humoral immune function following bone marrow transplantation; induction of terminal differentiation of acute lymphoblastoid leukemias; amelioration of immunodeficiency associated with hyper IgM; inhibition of the growth of solid tumors and B cell lymphomas; and reduction of inflammatory processes through down-regulation of production of IL-1, TNF, and IL-6. IL-4 has also been used in preclinical models to treat T cell-dependent autoimmune diseases, e.g., autoimmune diabetes mellitus and experimental and T cell-dependent allergic encephalomyelitis (Rapoport et al., 1993, J. Exp. Med. 178:87-99 and Racke et al., 1994, J. Exp. Med. 180:1961). Hence, IL-4 may be used in treating a variety of pathologies involving T cell-dependent immune activities.
IL-5 has been shown to induce eosinophil colonies in human liquid bone marrow cultures to induce antibody-mediated killing of tumor cells by peripheral blood eosinophils. IL-5 also has been shown to stimulate murine B cells to differentiate and proliferate and to simulate IgA and IgM secretion in B cells. IL-5 is useful for treating pathologies related to alterations in eosinophil activity. For example, suggested uses of IL-5 include treatment of schistosomiasis (see, e.g., Sanderson, April, 1989, “International Conference on the Clinical Impact of Interleukins” at the Royal College of Physicians in London). Other reports suggest the use of IL-5 in treating patients having certain tumors (see, e.g., Kolb et al., 1979, Br. J. Cancer 40:410; Pretlow et al., 1983, Cancer Res. 43:2997; and Iwasaki et al., 1986, Cancer 58:1321).
IL-6 is reported to exhibit multiple functions, including induction of proliferation in a number of cells, including EBV-transformed B cells, T cells, mesangial cells, and keratinocytes; enhancement of the IL-3-dependent proliferation of multipotential hematopoietic progenitors; promotion of megakaryocyte maturation; triggering of neuronal differentiation; growth inhibition of certain melanoma cell lines, myeloid leukemic cell lines, and breast carcinoma cell lines; i
Steele Alan
Strom Terry B.
Zheng Xin Xiao
Beth Israel Hospital Association
Fish & Richardson P.C.
Mertz Prema
LandOfFree
Treatment regimes featuring an IL-10-containing chimeric... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment regimes featuring an IL-10-containing chimeric..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment regimes featuring an IL-10-containing chimeric... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2962260